RCM
SLNO

Riverloft Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Riverloft Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-333
Closed -$37K – 58
2014
Q4 		$37K Buy
+333
New +$68.6K 0.02% 57

Other funds holding SLNO

BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Riverloft Capital Management's SLNO Position: Q1 2015 in Review

Riverloft Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2015, closing a stake of 333 shares — an estimated $37K sold.

Riverloft Capital Management first reported a position in SLNO in Q4 2014 and held it in 1 quarter. The position peaked at $37K in Q4 2014. 5 funds tracked by Wall St. Rank hold SLNO as of Q1 2015.

  • Riverloft Capital Management reported no remaining Soleno Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Riverloft Capital Management sold 333 Soleno Therapeutics shares in Q1 2015, an estimated $37K.
  • Riverloft Capital Management first reported a position in Soleno Therapeutics in Q4 2014 and held it in 1 quarter.
  • Riverloft Capital Management's Soleno Therapeutics position peaked at $37K in Q4 2014.
  • 5 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2015.

Based on Riverloft Capital Management's 13F filing for Q1 2015, filed 13 May 2015.